Facts About New advancements in BRD4 inhibition therapy ABBV-744 Revealed
In Section C, participants will get ABBV-744 and oral navitoclax. In Phase D, individuals will acquire ABBV-744 and ruxolitinib. Participants will obtain treatment right up until condition progression or perhaps the contributors are not able to tolerate the study drugs.There might be greater treatment load for contributors In this particular trial